ZA201406082B - Use of ccr3-inhibitors - Google Patents

Use of ccr3-inhibitors

Info

Publication number
ZA201406082B
ZA201406082B ZA2014/06082A ZA201406082A ZA201406082B ZA 201406082 B ZA201406082 B ZA 201406082B ZA 2014/06082 A ZA2014/06082 A ZA 2014/06082A ZA 201406082 A ZA201406082 A ZA 201406082A ZA 201406082 B ZA201406082 B ZA 201406082B
Authority
ZA
South Africa
Prior art keywords
ccr3
inhibitors
Prior art date
Application number
ZA2014/06082A
Other languages
English (en)
Inventor
Michael Chadham Nivens
Rolf Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201406082(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA201406082B publication Critical patent/ZA201406082B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
ZA2014/06082A 2012-04-03 2014-08-19 Use of ccr3-inhibitors ZA201406082B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
ZA201406082B true ZA201406082B (en) 2019-01-30

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/06082A ZA201406082B (en) 2012-04-03 2014-08-19 Use of ccr3-inhibitors

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP4389217A3 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20220132012A (enExample)
CN (2) CN110384699A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
EP3449866B1 (en) 2016-11-24 2021-10-20 Kirishima Seiko Co., Ltd. Orthodontic appliance
US11382907B2 (en) * 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
EA201992356A1 (ru) * 2017-04-05 2020-03-23 Алкахест Инк. Способ и композиция для лечения заболевания, связанного с сетчаткой глаза, с использованием ингибитора ccr3
CA3076017A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
EP3856195A4 (en) * 2018-09-26 2022-06-22 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS
US12692301B2 (en) 2020-06-11 2026-07-28 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
GB2361704C (en) * 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
KR20250133980A (ko) 2025-09-09
US20170319567A1 (en) 2017-11-09
AU2013245027B2 (en) 2017-10-12
ES2987267T3 (es) 2024-11-14
KR20220132012A (ko) 2022-09-29
BR112014023795A2 (enExample) 2017-06-20
PT2833884T (pt) 2020-08-26
EP4389217A3 (en) 2024-08-28
NZ628882A (en) 2016-05-27
SI2833884T1 (sl) 2020-10-30
EA201401083A1 (ru) 2015-03-31
CN104220073A (zh) 2014-12-17
US20130261153A1 (en) 2013-10-03
JP2018080183A (ja) 2018-05-24
ES2811554T3 (es) 2021-03-12
WO2013149986A1 (en) 2013-10-10
PL2833884T3 (pl) 2020-11-02
BR112014023795A8 (pt) 2017-10-10
EP4389217A2 (en) 2024-06-26
JP2015512432A (ja) 2015-04-27
HUE051648T2 (hu) 2021-03-29
MX2014011786A (es) 2014-12-05
KR20200044988A (ko) 2020-04-29
DK2833884T3 (da) 2020-08-10
IL234262A (en) 2017-10-31
CN110384699A (zh) 2019-10-29
US20200375971A1 (en) 2020-12-03
KR20140144200A (ko) 2014-12-18
LT2833884T (lt) 2020-09-10
CA2869269C (en) 2020-06-30
HRP20201165T1 (hr) 2020-12-11
AU2013245027A1 (en) 2014-09-11
EP3763369B1 (en) 2024-02-28
EP2833884B1 (en) 2020-05-20
CL2014002523A1 (es) 2015-01-23
BR112014023795B1 (pt) 2021-09-08
EA032263B1 (ru) 2019-05-31
CA2869269A1 (en) 2013-10-10
PH12014502239A1 (en) 2014-12-15
SMT202000499T1 (it) 2020-11-10
EP2833884A1 (en) 2015-02-11
RS60665B1 (sr) 2020-09-30
CY1123222T1 (el) 2021-10-29
EP3763369A1 (en) 2021-01-13
US20150099783A1 (en) 2015-04-09
KR20210063481A (ko) 2021-06-01
IN2014DN06989A (enExample) 2015-04-10
US20160081998A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
ZA201501847B (en) Formulations of enzalutamide
SG10201609940RA (en) Compounds and their methods of use
DK3327112T3 (en) Agse-deficient stamme
DK2830816T3 (en) Hidtil ukendt coatingkoncept
ZA201409503B (en) Disposable circumcising anastomat
EP2935220A4 (en) PERI-carbinol
SMT202000499T1 (it) Uso di inibitori-ccr3
GB201216800D0 (en) Novel use
GB201513279D0 (en) Micro-evolution of microbes
EP2920142A4 (en) MÉTHANOFULLERRÈNES
GB201501016D0 (en) Preparation of 18F-fluciclovine
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
GB201212463D0 (en) Novel use
TWM433525U (en) Structure of calorifier
GB201206393D0 (en) Use
GB201202256D0 (en) Novel use
GB201217666D0 (en) Construction of surfaces
GB201213726D0 (en) Novel compounds and their use
GB201209895D0 (en) Use of a composition
GB201220595D0 (en) Keysafe application
GB201206973D0 (en) New compounds and uses
GB201207075D0 (en) New compounds and uses
GB201206055D0 (en) New compounds and uses
GB201216165D0 (en) Virtues iBrush